The biotech industry offers a compelling investment opportunity due to its potential for disruptive innovations and high ...

The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM: US, France, Germany, Italy, Spain, ...

CMS is expected to announce in early 2025 the list of up to 15 Medicare Part D drugs that will be subject to price negotiations in 2025, with negotiated prices expected to be implemented in 2027.

Having begun working together in December 2015, the partners are now ready to bring to market their custom digital sensor for GSK’s asthma and COPD inhaler, Ellipta. The sensor attaches to the ...